Amplifon (AMP) investor relations material

Executive summary

• Q3 revenue was €575.0m, with 3.6% organic growth; adjusted EBITDA rose 7.0%, adjusted EBIT 21.9%, and adjusted net profit 38.7%.

• 9M revenue reached €1,760.8m with 3.5% organic growth; adjusted profitability and free cash flow improved.

• 2026 outlook was reaffirmed: organic growth above 3% and adjusted EBITDA margin expansion in the region of 100 bps.

Financial highlights

• Q3 revenue grew 2.1% at current exchange rates and 0.2% at constant rates; adjusted EBITDA was €114.8m, with a 20.0% margin, up 90 bps.

• Q3 adjusted EBIT was €52.2m, up 21.9%, with a 9.1% margin, up 150 bps; adjusted net profit rose 38.7% to €26.6m.

• 9M revenue grew 1.0% at current exchange rates and 0.9% at constant rates; organic growth was 3.5%.

• 9M adjusted EBITDA was €412.8m, up 4.5%, with a 23.4% margin, up 80 bps; adjusted EBIT rose 11.5% to €222.0m, with a 12.6% margin, up 120 bps.

• 9M adjusted net profit increased 16.9% to €128.2m; adjusted EPS rose 8.0% to €0.530.

Outlook and guidance

• 2026 guidance was confirmed: organic growth above 3% and adjusted EBITDA margin increase in the region of 100 bps, assuming no further global economic slowdown.

• The forecast assumes global market demand growth in the region of 3% versus 2025, with outperformance and market-share gains in key individual markets.

• GN Hearing integration planning was progressing to schedule; closing was expected by year-end, subject to approvals, customary conditions and carve-out completion.